KRW/ZAR Price & Performance (KRWZAR)

William Blair recently upgraded Kezar Life Sciences' stock to "Outperform," citing promising developments in its clinical pipeline, particularly for autoimmune hepatitis and lupus nephritis. Analysts are optimistic about zetomipzomib's potential, despite some safety concerns. Kezar's strong liquidity and upcoming trial results could significantly impact its market standing.1

Kezar Life Sciences is set to release its quarterly earnings on March 13. Analysts predict a loss of $2.71 per share. The stock has shown volatility, with a 12-month high of $10.50 and a low of $5.20. The upcoming earnings release will provide further insight into the company’s financial health.2

Amundi has reduced its holdings in Kezar Life Sciences by 90%, selling over 74,000 shares. The move reflects broader institutional adjustment, as other funds have also modified their positions. Kezar’s stock has faced challenges, with its market cap at $42.97 million and a year-low price of $5.20.3